Vol.

No.

July 25, 2025Jul 25, 2025

DOWNLOAD THE PDF

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

Cover Story

Clinical Conversation with The Cancer Letter

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

By Sara Willa Ernst, Jacquelyn Cobb and Paul Goldberg

The first large cancer screening/early detection initiative to be launched in 2025—the NCI-funded Vanguard study of multi-cancer detection tests—has started accruing patients through nine sites across the U.S.

Conversation with The Cancer Letter

Robert Winn: If Medicaid gets massive cuts or goes away, where will these patients get care?

By Sara Willa Ernst

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya

By Claire Marie Porter

City of Hope brings evidence-based approaches to integrative oncology

By Richard T. Lee

Podcast

In The Headlines: Is early detection always good? Inside NCI’s MCD feasibility trial.

Cancer Policy

FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts

Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad

The effects of NIH, FDA cuts will be felt for decades, CBO report estimates

COI statement prohibits “unseemly advocacy,” “undue influence” by industry rep on ODAC

Columbia settles with Trump, agreeing to a $200M fine, as Harvard fights on

In Brief

Shane Jacobson named CEO of the American Cancer Society, ACS CAN

Six researchers awarded $5.3M for pancreatic cancer research by Stephenson Global

Dispatch Bio aims to deliver universal treatment across solid tumors with novel immunotherapy approach

Research!America President & CEO Mary Woolley to step down in early 2026

Weill Cancer Hub West secures $200M to support launch of UCSF-Stanford collaboration

Sharad Goyal and Christina Puchalski receive endowed professorships at George Washington University Cancer Center

Rob Brainin appointed CEO of Champions Oncology

Geraldine O’Sullivan Coyne to lead early-stage clinical trials at Northwell’s START Center for Cancer Research

SITC Forward Fund announces 2025 fellowship recipients

Henry Ford + MSU researchers granted $3M from NIH to study HPV-positive head-and-neck cancers

UAMS Winthrop P. Rockefeller Cancer Institute, ARcare partner to boost CRC screenings in rural Arkansas

Funding Opportunities

FDA OCE issues RFA for cooperative agreements for evaluation of cardiotoxicity

Clinical Roundup

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

ChristianaCare research reveals drivers behind advanced breast cancer in hotspots

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Van Andel scientists develop improved single-cell DNA methylation technique

Researchers develop nicotinamide N-methyl transferase inhibitor to block ovarian cancer tumor growth

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

Secretogranin 2 binds LILRB4 resulting in immunosuppression, UT Southwestern study suggests

Drugs & Targets

FDA extends review period for Blenrep combinations after unfavorable ODAC vote, EU approval

FDA issues CRL for RP1+ nivolumab BLA for treatment of advanced melanoma

FDA grants Breakthrough Therapy designation to elironrasib for lung cancer

EC approves Cabometyx for advanced neuroendocrine tumors

EMA grants Orphan Drug designation for ICT01 as treatment for AML

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 41 - November 06, 2026